Senvest Management LLC Invests $33.88 Million in Intercept Pharmaceuticals, Inc. (ICPT)

Senvest Management LLC bought a new position in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 583,790 shares of the biopharmaceutical company’s stock, valued at approximately $33,883,000. Intercept Pharmaceuticals comprises about 2.2% of Senvest Management LLC’s portfolio, making the stock its 18th largest position. Senvest Management LLC owned approximately 2.33% of Intercept Pharmaceuticals as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in ICPT. Teachers Advisors LLC grew its stake in shares of Intercept Pharmaceuticals by 3.0% in the first quarter. Teachers Advisors LLC now owns 15,871 shares of the biopharmaceutical company’s stock worth $1,795,000 after acquiring an additional 461 shares during the last quarter. Aperio Group LLC purchased a new stake in shares of Intercept Pharmaceuticals in the second quarter worth $212,000. Public Employees Retirement Association of Colorado grew its stake in shares of Intercept Pharmaceuticals by 1.1% in the second quarter. Public Employees Retirement Association of Colorado now owns 4,111 shares of the biopharmaceutical company’s stock worth $498,000 after acquiring an additional 43 shares during the last quarter. Janney Montgomery Scott LLC grew its stake in shares of Intercept Pharmaceuticals by 1.8% in the second quarter. Janney Montgomery Scott LLC now owns 3,435 shares of the biopharmaceutical company’s stock worth $416,000 after acquiring an additional 62 shares during the last quarter. Finally, Candriam Luxembourg S.C.A. grew its stake in shares of Intercept Pharmaceuticals by 14.0% in the second quarter. Candriam Luxembourg S.C.A. now owns 24,500 shares of the biopharmaceutical company’s stock worth $2,966,000 after acquiring an additional 3,000 shares during the last quarter. 73.79% of the stock is currently owned by hedge funds and other institutional investors.

A number of equities research analysts have recently commented on the company. Citigroup reissued a “neutral” rating and issued a $150.00 target price on shares of Intercept Pharmaceuticals in a research note on Tuesday, September 19th. UBS cut Intercept Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Friday, September 22nd. Cowen reissued a “buy” rating and issued a $112.00 target price on shares of Intercept Pharmaceuticals in a research note on Wednesday, November 1st. Oppenheimer reissued a “hold” rating on shares of Intercept Pharmaceuticals in a research note on Tuesday, October 24th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Intercept Pharmaceuticals in a research note on Wednesday, November 1st. Three research analysts have rated the stock with a sell rating, ten have issued a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. Intercept Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $144.13.

Shares of Intercept Pharmaceuticals, Inc. (NASDAQ ICPT) opened at $61.21 on Monday. The company has a debt-to-equity ratio of 3.15, a quick ratio of 5.95 and a current ratio of 5.95. Intercept Pharmaceuticals, Inc. has a 12-month low of $54.98 and a 12-month high of $135.59.

Intercept Pharmaceuticals (NASDAQ:ICPT) last released its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($2.89) EPS for the quarter, beating the consensus estimate of ($3.48) by $0.59. Intercept Pharmaceuticals had a negative return on equity of 176.51% and a negative net margin of 344.74%. The company had revenue of $41.33 million for the quarter, compared to analysts’ expectations of $36.95 million. During the same period last year, the firm posted ($3.59) earnings per share. Intercept Pharmaceuticals’s revenue was up 697.9% compared to the same quarter last year. analysts anticipate that Intercept Pharmaceuticals, Inc. will post -13.35 earnings per share for the current year.

In other Intercept Pharmaceuticals news, CEO Mark Pruzanski sold 1,532 shares of the firm’s stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $58.87, for a total value of $90,188.84. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders have sold 2,566 shares of company stock worth $151,025 over the last ninety days. 9.20% of the stock is currently owned by insiders.

ILLEGAL ACTIVITY WARNING: “Senvest Management LLC Invests $33.88 Million in Intercept Pharmaceuticals, Inc. (ICPT)” was posted by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this report on another publication, it was stolen and republished in violation of United States & international copyright and trademark laws. The correct version of this report can be viewed at https://sportsperspectives.com/2017/12/04/senvest-management-llc-invests-33-88-million-in-intercept-pharmaceuticals-inc-icpt.html.

Intercept Pharmaceuticals Profile

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Institutional Ownership by Quarter for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply